Elabscience®


Recombinant Human PD-L1 Protein(Sumo Tag)

Catalog Number: PDEH101109

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description	
Species	Human
Source	E.coli-derived Human PD-L1 protein Phe19-Arg238, with an N-terminal Sumo
Calculated MW	37.1 kDa
Observed MW	43 kDa
Accession	Q9NZQ7
Bio-activity	Not validated for activity
Properties	
Purity	> 85% as determined by reducing SDS-PAGE.
Endotoxin	< 10 EU/mg of the protein as determined by the LAL method
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80
	°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 °C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with 5% Trehalose and 5%
	Mannitol.
Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of
	0.5 mg/mL. Concentration is measured by UV-Vis.

Data



SDS-PAGE analysis of Human PD-L1 proteins, 2µg/lane of Recombinant Human PD-L1 proteins was resolved with SDS-PAGE under reducing conditions, showing bands at 43 kDa

Background

Elabscience®

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.